Axsome Therapeutics Revenue Surges 66%
Axsome Therapeutics demonstrated robust revenue growth in Q4 2024, outpacing expectations despite higher-than-anticipated losses.
Biopharmaceutical firm Axsome Therapeutics (NASDAQ:AXSM) reported mixed fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 18. The company achieved substantial revenue growth, with sales hitting $118.8 million, surpassing analyst estimates of $118 million. However, its adjusted earnings per share (EPS) loss of $1.54 missed expectations of a $1 per share loss by a wide margin.
The quarter was marked by strong sales from its commercial products, Auvelity and Sunosi, and heightened strategic investment in research and development (R&D) reflected in increased spending.
Source: Axsome Therapeutics. Note: Analyst consensus estimates for the quarter provided by FactSet. YOY = Year over year.
